

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

DPYSL3 RABBIT PAB

货号: S218704

产品全名: DPYSL3 兔多抗

基因符号 DRP3; ULIP; CRMP4; DRP-3; LCRMP; CRMP-4; ULIP-1

UNIPROT ID: Q14195 (Gene Accession - BC039006)

背景: Necessary for signaling by class 3 semaphorins and subsequent remodeling of the cytoskeleton. Plays a role in axon guidance,

neuronal growth cone collapse and cell migration (By similarity).

抗原: Fusion protein of human DPYSL3

经过测试的应用: ELISA, WB, IHC

推荐稀释比: IHC: 50-100;WB: 1000-5000;ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse, Rat

成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol


研究领域: Neuroscience

储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Product Description


Pioneering GTPase and Oncogene Product Development since 2010




Immunohistochemistry analysis of paraffin embedded Human breast cancer tissue using 218704(DPYSL3 Antibody) at a dilution of 1/55(Cytoplasm).




In comparision with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with the fusion protein and then with 218704(Anti-DPYSL3 Antibody) at dilution 1/55.



The image on the left is immunohistochemistry of paraffinembedded Human esophagus cancer tissue using 218704(Anti-DPYSL3 Antibody) at a dilution of 1/55.



In comparision with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with fusion protein and then with D225022(Anti-DPYSL3 Antibody) at dilution 1/55.



Gel: 8%SDS-PAGE, Lysate: 40 µg; Lane 1-3: Mouse brain tissue, Human cerebella tissue, Human cerebrum tissue lysates; Primary antibody: 218704(DPYSL3 Antibody) at dilution 1/800; Secondary antibody: HRP-conjugated Goat anti rabbit IgG at 1/5000 dilution; Exposure time: 10 seconds



Product Description

Pioneering GTPase and Oncogene Product Development since 2010